Ascletis Pharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ascletis Pharma Inc. - overview
Established
2013
Location
Hangzhou, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2013 and based in Hangzhou, China, Ascletis Pharma Inc. operates as a pharmaceutical company which focuses on developing and manufacturing drugs in 3 areas, that is anti-viral (especially anti-HIV), cancer and fatty liver disease. The company has set up a production base in Shaoxing which has acquired drug production licence. The CFO, John P.
Gargiulo, graduted from Duke University. It has cooperated with Roche Holding. In January 2017, Ascletis Pharma Inc. raised USD 100 million in series B financing led by returning investor C-Bridge Capital.
In 2018, it was listed on the Hong Kong Stock Exchange. Ascletis focuses on the research, development and commercialization of innovative drugs in the fields of viral diseases, metabolic diseases, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors). Products include Gonovo, Ravidasvir and ASC21, etc. The company generates revenue by developing innovative drugs for the treatment of diseases such as antiviral, cancer and fatty liver.
Current Investors
Goldman Sachs Asset Management, W.T.T. Investment, Focus Media Information Technology
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.ascletis.com.cn
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.